Premium
Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4‐week period: a case series
Author(s) -
RuizVillaverde R,
SánchezCano D,
BurkhardtPérez P
Publication year - 2009
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2008.03019.x
Subject(s) - imiquimod , medicine , basal cell carcinoma , dermatology , basal cell , carcinoma , basal (medicine) , pathology , insulin
Basal cell carcinoma (BCC) is a malignant cutaneous neoplasm with a tendency to spread locally and with several clinical and histological subsets. We studied 82 patients with a clinical diagnosis of superficial BCC on different anatomical locations, to whom imiquimod 5% cream was administered on a low‐frequency regime (three times a week for 4 weeks), and who were followed up 2 years after completion of treatment. Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of superficial BCC in patients with associated comorbidities. Conflicts of interest None declared